MedTrace Logo

The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway

NCT00965120 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-10-25

No results posted yet for this study

Summary

Heart attacks are usually caused by a blood clot blocking an artery supplying blood to the heart. Current treatments are designed to relieve this blockage as quickly as possible to minimize damage to the heart muscle. However in restoring the supply of blood local damage known as "ischaemia-reperfusion injury" may occur. The aim of this study is to assess how clot forming and clot dissolving pathways are affected during this process, and examine the role of a natural inflammatory hormone, bradykinin. This will help the investigators to understand the mechanism by which ischaemia-reperfusion injury may occur and to devise new treatments for heart attacks.

Conditions

  • Ischaemic Heart Diseases

Interventions

PROCEDURE

Forearm vascular study

Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.

DRUG

bradykinin receptor antagonist (HOE-140)

Systemic infusion of bradykinin receptor antagonist (HOE-140).

DRUG

Placebo (saline)

Systemic infusion of placebo (saline).

Sponsors & Collaborators

  • University of Aarhus

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • David E Newby, PhD, FRCP · University of Edinburgh

  • Rajesh K Kharbanda, PhD, FRCP · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00965120 on ClinicalTrials.gov